Extended Data Fig. 5: Blood CXCR1 and CXCR2 cytokines after CXCR2i and enzalutamide.
From: Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
a–f, Individual patient circulating levels of CXCL1 (n = 14), CXCL2 (n = 20), CXCL5 (n = 20), CXCL6 (n = 13), CXCL7 (n = 13), CXCL8 (n = 20) by dose level. Missing patients did not have samples collected or samples that failed quality control. g,h,i, By-dose level, mean fold change in circulating CXCL5 (g, n = 20), CXCL6 (h, n = 13), and CXCL7 (i, n = 13) levels compared with baseline over time. Samples were taken at baseline, on day 1 of each cycle and day 15 of the first cycle. j,k,l, Scatterplot of CXCL1 (j, n = 14), CXCL2 (k, n = 20), CXCL8 (l, n = 20) fold change from baseline versus percent blood neutrophil count from baseline on cycle 2 day 1. Estimated linear regression lines (pink) with 95% confidence interval (grey band), and correlation coefficients and p-values from the two-sided Spearman’s rank correlation analyses are shown. m,n,o, Scatterplot of CXCL5 (n = 20) (m), CXCL6 (n = 13) (n), CXCL7 (n = 13) (o) fold change from baseline versus percent blood neutrophil count from baseline on cycle 2 day 1. Correlation coefficient and p-value from the two-sided Spearman’s rank correlation test are shown. Colour of the lines and dots represent AZD5069 dose. NR = non-responder, PR = partial responder. BD = twice daily.